2013 SINGLE TRIAL M Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection double-blind, randomized controlled trial 844 Objective: To assess the safety & efficacy of dolutegravir at a dose of 50 mg plus a fixed-dose combination of abacavir-lamivudine, as … Read More
